Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Recruiting

Phase 2

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Sponsor:

BioNTech SE

Code:

NCT06449222

Conditions

Locally Advanced Breast Cancer

Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancers

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BNT327 Dose Level 1 (DL1)

BNT327 Dose Level 1 (DL2)

Nab-placlitaxel

Carboplatin

Gemcitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by BioNTech SE on 2025-05-02.